AGENUS INC

Listed Company

AGENCIK 0001098972NasdaqAcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$114.20M

Net Income

$-3.08M

Total Assets

$226.80M

Equity

$-271.11M

Shares Out

38.40M

Op. Cash Flow

$-77.19M

Business

AGENUS INC is a clinical-stage biotechnology company that discovers and develops therapies to activate the immune system against cancer and infectious diseases. It develops immune‑modulatory antibodies, adoptive cell therapies and vaccine adjuvants, including lead antibody candidates botensilimab and balstilimab, allogeneic iNKT cell therapies via MiNK Therapeutics, and QS‑21 STIMULON adjuvants via SaponiQx. Its operations are organized across discovery, translational platforms, in‑house cGMP manufacturing, clinical development and subsidiary business units. The company advances programs globally through clinical trial centers, strategic partnerships, licenses and distribution channels.

Summary from filing dated 2025-03-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	114	103	156	98	296
Cost of revenue	−1	−486,000	−3	−11	−3
Research and development	−79	−156	−235	−187	−179
General and administrative	−54	−72	−79	−81	−76
Fair value adjustments	387,000	4	556,000	815,000	−11
Operating loss	−20	−120	−160	−179	26
Non-operating income (expense)	−2	6	37,000	13	5
MiNK Therapeutics, Inc. equity method investment fair value adjustment	−26	0	0	—	—
Gain from deconsolidation of MiNK Therapeutics, Inc.	101	0	0	—	—
Interest expense, net	−55	−118	−98	−62	−66
Net loss	−3	−232	−257	−231	−29
Dividends on Series A-1 convertible preferred stock	−216,000	−215,000	−213,000	−212,000	−211,000
Less: net loss attributable to non-controlling interest	−3	−5	−12	−11	−5
Net loss attributable to Agenus Inc. common stockholders	−101,000	−227	−246	−220	−24
Basic net loss attributable to Agenus Inc. common stockholders	0	−10.59	−13.75	−15.64	−0.11
Diluted net loss attributable to Agenus Inc. common stockholders	0	−10.59	−13.75	−15.64	−0.11
Basic	30	21	18	14	228,919
Diluted	30	21	18	14	228,919
Foreign currency translation gain (loss)	959,000	−443,000	−2	−577,000	−1
Other comprehensive income (loss)	959,000	−443,000	−2	−577,000	−1
Comprehensive income (loss)	858,000	−228	−248	−221	−25

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	3	40	76	179	292
Accounts receivable	2	407,000	26	3	2
Related party note receivable from MiNK Therapeutics, Inc.	5	—	—	—	—
Prepaid expenses	785,000	2	8	14	20
Assets held for sale	122	0	—	—	—
Other current assets	1	2	2	3	3
Total current assets	133	46	112	213	332
Property, plant and equipment, net of accumulated amortization and depreciation of $47,468 and $72,553 at December 31, 2025 and 2024, respectively	15	120	133	133	60
Operating lease right-of-use assets	8	27	30	31	31
Goodwill	24	24	25	25	25
Acquired intangible assets, net of accumulated amortization of $17,325 and $16,986 at December 31, 2025 and 2024, respectively	3	3	4	6	8
Equity method investment in MiNK Therapeutics, Inc.	24	0	—	—	—
Other long-term assets	3	6	9	4	10
Total assets	227	226	314	414	466
Current portion, long-term debt	45	3	146,000	575,000	728,000
Current portion, liability related to sale of future royalties and milestones	109	112	133	84	62
Current portion, deferred revenue	0	31,000	18,000	12	12
Current portion, operating lease liabilities	1	2	3	2	3
Accounts payable	83	61	61	41	30
Accrued liabilities	34	35	45	38	42
Liabilities held for sale	51	—	—	—	—
Other current liabilities	529,000	8	14	11	7
Total current liabilities	323	221	256	189	157
Long-term debt, net of current portion	0	30	13	13	13
Liability related to sale of future royalties and milestones, net of current portion	170	224	125	188	192
Deferred revenue, net of current portion	1	1	1	1	11
Operating lease liabilities, net of current portion	10	55	63	63	42
Other long-term liabilities	259,000	738,000	5	15	2
Commitments and contingencies (Note 20)	—	—	—	—	—
Common stock, par value $0.01 per share; 800,000,000 shares authorized at December 31, 2025 and 2024; 35,320,397 shares and 23,634,670 shares issued and outstanding at December 31, 2025 and 2024, respectively	353,000	236,000	197,000	3	3
Additional paid-in capital	1,912	1,858	1,796	1,645	1,520
Accumulated other comprehensive loss	−439,000	−1	−955,000	915,000	1
Accumulated deficit	−2,180	−2,183	−1,956	−1,710	−1,490
Total stockholders' deficit attributable to Agenus Inc.	−271	−326	−160	−61	34
Non-controlling interest	−7	20	12	6	13
Total stockholders' deficit	−278	−306	−148	−55	48
Total liabilities, convertible preferred stock and stockholders' deficit	227	226	314	414	466

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	10	13	14	7	7
Share-based compensation	14	17	23	18	20
Non-cash royalty revenue	−109	−101	−115	−45	−44
Non-cash interest expense	54	118	101	63	65
Loss (gain) on sale or disposal of assets, net	937,000	1	−1	−16	−3
Loss on impairment of assets	234,000	2	0	6	—
Gain on forgiveness of liability	0	−2	—	−3	—
Gain on lease terminations	0	−5	—	—	—
Unrealized loss on long-term investments	26	2	2	—	—
Other, net	3	−90,000	−119,000	—	—
Accounts receivable	−2	25	−23	122,000	−394,000
Prepaid expenses	1	6	6	12	−5
Accounts payable	24	2	21	6	11
Deferred revenue	1,000	20,000	−12	−10	−22
Accrued liabilities and other current liabilities	4	136,000	21	2	−1
Other operating assets and liabilities	−198,000	−691,000	−2	14	8
Net cash used in operating activities	−77	−158	−224	−175	10
Proceeds from sale of property, plant and equipment	359,000	24,000	3	22	6
Purchases of property, plant and equipment	−6,000	−576,000	−10	−53	−34
Purchases of available-for-sale securities	0	—	−15	−25	−15
Proceeds from sale of available-for-sale securities	0	—	30	25	—
Purchase of long-term investment	0	—	−5	—	—
Proceeds from sale of long-term investment	841,000	579,000	34,000	—	—
Net cash provided by investing activities	1	27,000	3	−34	−43
Net proceeds from sale of equity	36	33	133	99	198
Net proceeds from sale of subsidiary shares in private placement	0	6	—	—	—
Proceeds from employee stock purchases and option exercises	169,000	647,000	807,000	898,000	9
Purchase of treasury shares to satisfy tax withholdings	−87,000	—	−5	−4	−2
Purchase of subsidiary shares	0	—	−606,000	—	—
Proceeds from Ligand Purchase Agreement, net of expenses	0	74	—	—	—
Proceeds from the issuance of long-term debt, net	13	20	—	—	—
Impact to cash resulting from deconsolidation certain subsidiaries	−2	—	—	—	—
Payment of long-term debt	−3	—	—	—	—
Payment of finance lease obligations	−8	−10	−9	−490,000	−855,000
Net cash provided by financing activities	37	123	120	96	225
Effect of exchange rate changes on cash	47,000	−260,000	−628,000	−104,000	−164,000
Net decrease in cash, cash equivalents and restricted cash	−39	−36	−102	−113	192
Cash paid for interest	1	2	3	1	1
Issuance of stock options for payment of certain employee bonuses	0	9	—	—	—
Issuance of subsidiary shares for employee bonus	0	—	1	294,000	—
Insurance financing agreements	706,000	771,000	707,000	1	2
Lease right-of-use assets obtained in exchange for new operating lease liabilities	107,000	105,000	318,000	9	2
Lease right-of-use assets obtained in exchange for new finance lease liabilities	10	122,000	5	25	762,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro